Introduction {#section1-1076029618761005}
============

Angiographic no reflow, a reduced coronary antegrade flow (thrombolysis in myocardial infarction \[TIMI\] flow grade ≤2) without mechanical obstruction after recanalization, is known to be associated with short- and long-term morbidity and mortality in patients who underwent primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI),^[@bibr1-1076029618761005],[@bibr2-1076029618761005],[@bibr3-1076029618761005]^ and early identification of patients at high risk regarding no reflow is very important for the prevention and treatment of this condition. Previous studies have suggested various hematological parameters, such as the platelet-to-lymphocyte ratio (PLR),^[@bibr4-1076029618761005],[@bibr5-1076029618761005]^ mean platelet volume-to-lymphocyte ratio (MPVLR),^[@bibr6-1076029618761005]^ and neutrophil-to-lymphocyte ratio (NLR) to be inflammatory and thrombotic markers in patients with coronary atherosclerotic disease and may predict poor cardiovascular outcomes^[@bibr7-1076029618761005]^ and no reflow in patients with acute STEMI undergoing mechanical reperfusion.^[@bibr8-1076029618761005]^ However, the literature reports on the predictive value of these parameters vary, and data on the comparison of the utility of such parameters are rare or not available. So in this study, we aim to investigate the association between no-reflow and NLR, PLR, MPVLR, and other hematological parameters in patients with STEMI undergoing PPCI and compare the utility of these parameters for early detection of patients at high risk of no-reflow phenomenon.

Patients and Methods {#section2-1076029618761005}
====================

Study Population {#section3-1076029618761005}
----------------

Patients diagnosed with STEMI undergoing PPCI between September 2012 and October 2016 in our hospital were enrolled in this retrospective observational study. ST-segment elevation myocardial infarction was defined as typical chest pain \>30 minutes with ST-segment elevation of \>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle branch block and more than 2-fold increase in serum cardiac markers. Exclusion criteria included cardiogenic shock on admission, thrombolytic drugs in the previous 24 hours, active infections, systemic inflammatory disease history, clinical evidence of autoimmune disease or hematological proliferative disorders, known malignancy, liver disease as well as patients with renal failure. Demographic data (age and gender), history of diseases (diabetes mellitus, hypertension, and hyperlipidemia), and smoking status were collected in all patients. The study protocol was approved by the ethics committee of our institution, and written informed consent was obtained from all patients.

Coronary Angiography and PCI Procedure {#section4-1076029618761005}
--------------------------------------

Pharmacological treatment of all enrolled patients before PPCI included aspirin (300 mg loading dose), clopidogrel (600 mg loading dose), and an intravenous bolus of unfractionated heparin at a dose of 70 U/kg of body weight. The PPCI was performed using the standard radial or femoral approach with a 6F or 7F guiding catheter. The stent was deployed in all patients. The use of balloon predilatation or postdilatation, the type of stents (bare-metal or drug-eluting), and the use of thrombus aspiration were left to the operator's decision. The glycoprotein IIb/IIIa receptor inhibitor tirofiban was given by judgment of the operator and initiated during PCI procedure with 10 μg/kg intracoronary bolus followed by 0.15 μg/kg/min intravenous infusion. Technically, successful stent implantation was defined as the residual stenosis \<10% in the culprit lesion after the procedure as visually assessed by angiography, without occlusion of a significant side branch, flow-limiting dissection, distal embolization, or angiographic thrombus.^[@bibr9-1076029618761005]^ The TIMI flow grades were evaluated by consensus of 2 experienced interventional cardiologists who did not have knowledge of the clinical and laboratory data using the quantitative cardiovascular angiographic software. No reflow after PPCI was defined as TIMI flow grade ≤2 after vessel recanalization despite the absence of angiographic stenosis, spasm, dissection, or thrombosis. Normal reflow was defined as postintervention TIMI grade 3 flow.^[@bibr10-1076029618761005]^ Study participants were divided into 2 groups according to TIMI flow grades after PPCI. Multivessel disease was defined as \>50% diameter stenosis of 2 or more major epicardial coronary arteries. To evaluate the intracoronary thrombus burden, we performed TIMI thrombus scale^[@bibr11-1076029618761005]^ in all patients after antegrade flow achievement through guidewire crossing or small balloon dilatation (final TIMI thrombus grade). In TIMI thrombus grade 0, no cine-angiographic characteristics of thrombus are present; in TIMI thrombus grade 1, possible thrombus is present with angiographic characteristics such as decreased contrast density, haziness, irregular lesion contour, or a smooth convex "meniscus" at the site of total occlusion suggestive but not diagnostic of thrombus; in TIMI thrombus grade 2, there is definite thrombus, with the largest dimensions ≤1/2 the vessel diameter; in TIMI thrombus grade 3, there is definite thrombus with the largest linear dimension \>1/2 but \<2 vessel diameters; in TIMI thrombus grade 4, there is definite thrombus, with the largest dimension ≥2 vessel diameters; and in TIMI thrombus grade 5, there is total occlusion. Low-thrombus burden group was defined as a thrombus grade of 0 to 2, and high-thrombus burden was defined as a thrombus grade of at least 3.

Angiographic and procedural data (eg, time from symptom onset to PPCI, stent parameters) were collected for each participant.

Laboratory Analysis and Echocardiography {#section5-1076029618761005}
----------------------------------------

In all patients, venous blood samples were drawn into standard EDTA-containing tubes on admission in the emergency department before the administration of aspirin and clopidogrel. The hematological parameters such as neutrophil, platelet, and lymphocyte count were measured by an automated blood cell counter (XS-1000i; Sysmex Co, Kobe, Japan). Creatinine, high-sensitivity C-reactive protein (hs-CRP), and cardiac enzymes on admission were also measured in all patients determined by the standard methods. Echocardiography investigation was routinely performed on admission before PPCI, using GE ViVidE7 ultrasound machine (GE Healthcare, Piscataway, New Jersey) with a 3.5-MHz transducer. Left ventricular ejection fraction (LVEF) was measured by Simpson method in the 2-dimensional echocardiographic apical 4-chamber view.

Statistical Analysis {#section6-1076029618761005}
--------------------

Continuous variables with a normal distribution (eg, age, LVEF, peak cardiac troponin I \[cTnI\] level, and creatinine level) were expressed as a mean (SD), and the differences between groups were tested by independent samples *t* test. Continuous variables with nonnormal distribution (eg, hs-CRP and hematological parameters) were expressed as medians and interquartile ranges, and the differences between the groups were analyzed with Mann-Whitney *U* tests. Categorical variables were summarized as percentages and compared to the χ^2^ test. A 2-sided *P* value \<.05 was considered significant. Multivariate logistic regression analysis was used to identify independent predictors for the development of the no-reflow phenomenon. Receiver--operating characteristic (ROC) curves of the NLR, PLR, MPVLR, lymphocyte-to-monocyte ratio (LMR), lymphocyte count, and neutrophil count were drawn to compute the area under the curve (AUC). The Youden-index method was applied to set an optimal cutoff value for optimal differentiation. The DeLong test was used to compare ROC-AUCs of different parameters. Statistical analysis was performed using the SPSS 22.0 Statistical Package Program for Windows (SPSS Inc, Chicago, Illinois).

Results {#section7-1076029618761005}
=======

Our study included 612 patients (435 men; mean age: 62 \[14\] years) with STEMI who had undergone PPCI within 12 hours from symptom onset. In the current study, the incidence of the angiographic no-reflow phenomenon was 16.0% (n = 97) after PPCI. Patients with TIMI flow grades 0 to 2 formed the no-reflow group (n = 97; 67 men; mean age: 63 \[16\] years), and patients with TIMI 3 flow grade formed the normal reflow group (n = 515; 368 men; mean age: 62 \[13\] years), respectively. Baseline demographic and biochemical characteristics of the patients in no-reflow and normal reflow groups are shown in [Table 1](#table1-1076029618761005){ref-type="table"}.

###### 

Baseline Demographic and Biochemical Characteristics of Patients in Groups.

![](10.1177_1076029618761005-table1)

  Variables             Normal-reflow (n = 515)   No-reflow (n = 97)   *P*
  --------------------- ------------------------- -------------------- -------
  Age, years            62 (13)                   63 (16)              .477
  Male sex              368 (71.5%)               29 (69.1%)           .324
  Diabetes mellitus     164 (31.9%)               20 (30.3%)           1.000
  Hypertension          306 (59.5%)               63 (65.2%)           .426
  Hyperlipidemia        346 (67.3%)               45.5 (46.9%)         .335
  Active smokers        237 (46.2%)               32 (33.3%)           .213
  Prior MI              17 (3.5%)                 3 (3.0%)             1.000
  LVEF, %               53.6 (9.6)                52.4 (8.2)           .425
  Creatinine, µmol/L    78.0 (24.7)               81.3 (25.3)          .411
  hs-CRP level, mg/L    4.08 (1.51-11.50)         5.16 (1.86-13.47)    .654
  Peak cTnI, ng/mL^a^   35.9 (11.3-90.5)          59.7 (16.6-119.7)    .344

Abbreviations: cTnI, cardiac troponin I; hs-CRP, high sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; MI, myocardial infarction.

^a^Data are presented as the median value (25th, 75th percentiles).

There was no statistically significant difference between the 2 groups in the presence of hypertension, hyperlipidemia, diabetes mellitus, and previous myocardial infarction. Age, sex distribution, and serum creatinine admission LVEF levels were similar between the groups. Median peak cTnI levels were not significantly different between the no-reflow group and the normal reflow group (59.7 ng/mL vs 35.9 ng/mL; *P* = .344). There was no significant difference in median hs-CRP levels between the no-reflow group and the normal reflow group (5.16 mg/L vs 4.08 mg/L; *P* = .654).

The comparison of admission hematological parameters between 2 groups of patients is presented in [Table 2](#table2-1076029618761005){ref-type="table"}. White blood cell, platelet count, mean platelet volume (MPV), hemoglobin, hematocrit, and monocyte count were similar in both the groups. The patients in the no-reflow group had a significantly higher median neutrophil count (7.10 × 10^9^/L vs 6.30 × 10^9^/L; *P* = .031), NLR (4.45 vs 3.00; *P* = .004), PLR (131.20 vs 102.50; *P* = .006), MPVLR (6.71 vs 5.14; *P* = .027), but lower median lymphocyte count (1.50 × 10^9^/L vs 2.00 × 10^9^/L; *P* = .010) and LMR (3.25 vs 4.00; *P* = .008) when compared to the normal reflow patients.

###### 

Hematological Parameters of the Study Population.^a^

![](10.1177_1076029618761005-table2)

  Variable                                   Normal-reflow (n = 515)   No-reflow (n = 97)       *P*
  ------------------------------------------ ------------------------- ------------------------ ------
  White blood cell count, ×10^9^/L           9.10 (7.50-11.28)         9.81 (7.81-11.47)        .221
  Neutrophil count, ×10^9^/L                 6.30 (4.55-8.05)          7.10 (5.28-9.43)         .031
  Hemoglobin, g/dL                           148.00 (135.50-156.50)    142.00 (132.50-155.00)   .082
  Platelet count, ×10^9^/L                   206.00 (175.50-248.50)    216.50 (165.50-277.00)   .519
  Hematocrit, %                              43.10 (40.25-45.50)       41.40 (38.45-44.70)      .065
  Mean platelet volume, fL                   10.20 (9.70-10.90)        10.50 (9.80-11.10)       .303
  Lymphocyte count, ×10^9^/L                 2.00 (1.40-2.85)          1.50 (1.00-2.50)         .010
  Monocyte count, ×10^9^/L                   0.50 (0.40-0.70)          0.52 (0.40-0.70)         .748
  Neutrophil/lymphocyte ratio                3.00 (1.70-5.25)          4.45 (2.50-8.65)         .004
  Platelet/lymphocyte ratio                  102.50 (71.70-151.55)     131.20 (82.65-213.37)    .006
  Mean platelet volume-to-lymphocyte ratio   5.14 (3.51-7.46)          6.71 (4.01-9.93)         .027
  Lymphocyte-to-monocyte ratio               4.00 (3.00-5.00)          3.25 (2.38-4.57)         .008

^a^Data are presented as median (interquartile range).

The angiographic and procedural characteristics of the patient population are presented in [Table 3](#table3-1076029618761005){ref-type="table"}. No significant differences in the time from pain to intervention, infarct-related coronary artery, multivessel disease, and other angiographic or procedural characteristics were observed between the groups. However, the high-thrombus burden was more frequently observed in the no-reflow group compared to the normal reflow group (58.8% vs 29.2%; *P* = .000).

###### 

Angiographic and Procedural Characteristics of Study Population According to TIMI Flow.

![](10.1177_1076029618761005-table3)

  Variable                          Normal-reflow (n = 515)   No-reflow (n = 97)   *P*
  --------------------------------- ------------------------- -------------------- ------
  Time from symptom onset to PPCI                                                  .227
   \<3 hours                        145 (28.3%)               22 (22.7%)           
   3-6 hours                        198 (38.4%)               31 (31.8%)           
   6-12 hours                       171 (33.3%)               44 (45.5%)           
  Infarct-related coronary artery                                                  .748
   Left main                        2 (0.4%)                  0 (0.0%)             
   Left anterior descending         274 (53.2%)               50 (51.5%)           
   Left circumflex                  57 (11.0%)                15 (15.1%)           
   Right coronary artery            182 (35.4%)               32 (33.4%)           
  Multi-vessel disease              435 (84.4%)               69 (71.2%)           .225
  Proximal lesion                   291 (56.6%)               46 (47.0%)           .365
  Preintervention TIMI flow grade                                                  .548
   0                                470 (91.3%)               82 (84.5%)           
   1                                24 (4.6%)                 9 (9.3%)             
   2                                15 (2.9%)                 5 (5.2%)             
   3                                6 (1.2%)                  1 (1.0%)             
  Thrombus burden                                                                  .000
   Low thrombus burden              365 (70.8%)               40 (41.2%)           
   High thrombus burden             150 (29.2%)               57 (58.8%)           
  Number of used stent, n           1.59 (0.70)               1.41 (0.94)          .149
  Stent length, mm                  36.18 (18.21)             37.75 (20.53)        .618
  Stent diameter, mm                3.08 (0.46)               3.16 (0.44)          .310
  Use of thrombus aspiration        116 (22.5%)               44 (45.5%)           .000
  Tirofiban use                     284 (55.2%)               81 (83.3%)           .000

Abbreviations: PPCI, primary percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.

The multivariate logistic regression models revealed that neutrophil count (odds ratio \[OR\] = 1.122, 95% confidence interval \[CI\]: 1.007-1.250; *P* = .037), lymphocyte count (OR = 0.701, 95% CI: 0.509-0.965; *P* = .029), NLR (OR = 1.010, 95% CI: 1.020-1.188; *P* = .014), PLR (OR = 1.005, 95% CI: 1.001-1.009; *P* = .013), MPVLR (OR = 1.076, 95% CI: 1.001-1.157; *P* = .045), LMR (OR = 0.812, 95% CI: 0.682-0.966; *P* = .019), and thrombus burden (OR = 3.526, 95% CI: 1.858-6.695; *P* = .000) were independent factors for predicting no-reflow phenomenon in patients undergoing PPCI after adjustment for age, gender, history of hypertension, diabetes mellitus, hyperlipidemia, active smoking, preintervention TIMI flow grade, and hs-CRP level, as shown in [Table 4](#table4-1076029618761005){ref-type="table"}.

###### 

Odd ratios (ORs) of Prognostic Factors for Predicting No-Reflow.^a,b^

![](10.1177_1076029618761005-table4)

  Factors                           Model 1               Model 2                         
  --------------------------------- --------------------- --------- --------------------- ------
  Preintervention TIMI flow grade   1.371 (0.847-2.217)   .199                            
  Thrombus burden                   3.454 (1.847-6.460)   .000      3.526 (1.858-6.695)   .000
  hs-CRP                            0.997 (0.988-1.006)   .526                            
  Neutrophil count                  1.112 (1.010-1.224)   .030      1.122 (1.007-1.250)   .037
  Lymphocyte count                  0.696 (0.512-0.947)   .021      0.701 (0.509-0.965)   .029
  NLR                               1.120 (1.044-1.201)   .002      1.101 (1.020-1.188)   .014
  PLR                               1.006 (1.002-1.010)   .003      1.005 (1.001-1.009)   .013
  MPVLR                             1.080 (1.010-1.155)   .025      1.076 (1.001-1.157)   .045
  LMR                               0.793 (0.665-0.945)   .010      0.812 (0.682-0.966)   .019

Abbreviations: CI, confidence interval; hs-CRP, high sensitivity C-reactive protein; LMR, lymphocyte-to-monocyte ratio; MPVLR, mean platelet volume-to-lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; TIMI, thrombolysis in myocardial infarction.

^a^Model 1: unadjusted model.

^b^Model 2: adjusted for age, gender, history of hypertension, diabetes mellitus, hyperlipedemia, active smoking, preintervention TIMI flow grade and hs-CRP.

Information on the cutoff values and capacity of the individual hematological parameters to predict no-reflow phenomenon in patients with STEMI is provided in [Table 5](#table5-1076029618761005){ref-type="table"}. Neutrophil-to-lymphocyte ratio provided largest AUC for predicting no reflow (AUC-ROC: 0.628, 95% CI: 0.569-0.685; *P* = .028). Using 2.8 as a cutoff value, the assessed sensitivity was 74.0%, with 47.6% specificity, 89.3% negative predictive value, and 23.7% positive predictive value. No statistically significant difference in ROC-AUC was found among evaluated parameters ([Figure 1](#fig1-1076029618761005){ref-type="fig"}).

###### 

Predictive Capacities of Hematological Parameters for No-Reflow.

![](10.1177_1076029618761005-table5)

  Parameters                   ROC-AUC (95% CI)      *P* Value   Cutoff Value   Sensitivity   Specificity   Negative Predictive Value   Positive Predictive Value
  ---------------------------- --------------------- ----------- -------------- ------------- ------------- --------------------------- ---------------------------
  Neutrophil count, ×10^9^/L   0.597 (0.537-0.655)   .027        5.1            82.0          37.1          90.4                        22.3
  Lymphocyte count, ×10^9^/L   0.616 (0.556-0.673)   .010        1.4            48.0          72.1          86.3                        27.4
  NLR                          0.628 (0.569-0.685)   .028        2.8            74.0          47.6          89.3                        23.7
  PLR                          0.624 (0.565-0.681)   .005        142.3          48.0          74.2          86.7                        29.0
  MPVLR                        0.600 (0.540-0.658)   .028        6.69           54.0          66.8          86.2                        27.5
  LMR                          0.620 (0.560-0.677)   .008        2.97           46.0          77.7          86.1                        32.5

Abbreviations: CI, confidence interval; LMR, lymphocyte-to-monocyte ratio; MPVLR, mean platelet volume-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; ROC-AUC, receiver operating characteristic-area under the curve.

![ROC-curves of various parameters for predicting no-reflow. For comparison between assessed hematologic parameters, the DeLong test was applied, no statically significant differences were found among evaluated hematologic parameters. LMR indicates lymphocyte-to-monocyte ratio; MPVLR, mean platelet volume-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; ROC, receiver operating characteristic.](10.1177_1076029618761005-fig1){#fig1-1076029618761005}

Discussion {#section8-1076029618761005}
==========

In the present study, we demonstrated the predicting value of MPVLR for the no-reflow phenomenon in patients with STEMI for the first time. However, we found no significant differences in the hematological parameters on admission in the predictive power for the no-reflow phenomenon.

Despite successful recanalization of the infarct-related artery for patients with acute STEMI, myocardial tissue perfusion does not completely restore in up to 12% to 39% of patients.^[@bibr2-1076029618761005],[@bibr12-1076029618761005]^ This effect is known as the no-reflow phenomenon, which may markedly reduce the benefits of recanalization of the ischemic-related artery and is associated with short-term and long-term adverse clinical outcomes.^[@bibr13-1076029618761005],[@bibr3-1076029618761005]^ In the present study, 66 (16.0%) patients developed angiographic no reflow. The limited access to performant diagnostic tools or biomarkers restricts the therapeutic window in PPCI practice for patients with STEMI. Early risk stratification to detect patients at high risk of no reflow before PPCI may be beneficial from perspective awareness of this condition, which might lead to the use of certain prophylactic interventional techniques^[@bibr14-1076029618761005]^ or intracoronary medications to ameliorate the development of no reflow.^[@bibr15-1076029618761005]^ Although the pathophysiology of the no-reflow phenomenon has not been fully understood, previous studies have suggested important roles for inflammation^[@bibr16-1076029618761005]^ and excessive thrombotic activity,^[@bibr15-1076029618761005]^ which may eventually lead to distal microvascular obstruction and endothelial dysfunction in the process of no-reflow phenomenon. The complete blood count is inexpensive and routinely available on admission before PPCI and includes several inflammatory parameters. Previous studies, including ours, have reported that higher neutrophil count,^[@bibr17-1076029618761005]^ lower lymphocyte count,^[@bibr18-1076029618761005]^ MPV,^[@bibr19-1076029618761005]^ NLR,^[@bibr7-1076029618761005],[@bibr8-1076029618761005]^ PLR,^[@bibr4-1076029618761005],[@bibr5-1076029618761005]^ and MPVLR^[@bibr6-1076029618761005]^ seem to have association with the pathogenesis of no-reflow phenomenon and prognostic value in STEMI. To the best of our knowledge, this is the first study to determine the comparative value of these parameters in predicting the no-reflow phenomenon for patients with STEMI treated with PPCI. Our study showed that for the prediction of no reflow in patients with STEMI who underwent PPCI, no hematological parameters such as neutrophil count, lymphocyte count, MPV, NLR, PLR, or MPVLR displayed persuasive discriminatory capacities. In the present study, neutrophil count and NLR had moderately high sensitivities (82.0% and 74.0%, respectively) and negative predictive value (90.4%, 89.3%, respectively) in the current study, although the specificities and positive predictive value were relatively low.

Neutrophil infiltration was found in ruptured plaques in patients with acute coronary syndromes.^[@bibr20-1076029618761005]^ Accumulation of neutrophils in capillaries probably contributed to microvascular obstruction and no-reflow development.^[@bibr21-1076029618761005]^ Neutrophil-to-lymphocyte ratio, an index that reflects high neutrophil levels and relatively low lymphocyte count, has been determined to be a good indicator of inflammatory conditions.^[@bibr22-1076029618761005]^ In the present study, the predictive value examined using ROC curve analysis revealed that, although without significant difference, NLR \>2.8 (AUC = 0.628) had the higher discriminative ability for predicting the no reflow than neutrophil count \>5.1 × 10^9^/L (AUC = 0.597). One possible reason may be that NLR represents a combination of 2 important and opposite immune pathways, where neutrophils represent nonspecific systemic inflammation initiating the first line of defense, whereas lymphocytes represent the regulatory or protective component of the immune system physiological stress response. This may explain that NLR performs better than absolute neutrophil count alone in our study. Moreover, NLR has better stability compared to the neutrophil count, which may be altered by various physiological, pathological, and physical factors.^[@bibr23-1076029618761005]^ The finding of no statistically significant result for the predictive value of neutrophil count and NLR in the current study may due to the retrospective nature and small sample size.

Furthermore, we identified PLR and MPVLR to have a moderate predictive value (AUC = 0.624 and 0.600, respectively) and high specificity (74.2%, 66.8%, respectively) for no-flow phenomenon. Higher platelet count and MPV may reflect underlying inflammation, platelet activation, and higher propensity to form thrombi.^[@bibr24-1076029618761005],[@bibr25-1076029618761005]^ Kurtul et al revealed that PLR is a strong and independent predictor of no reflow after PPCI.^[@bibr26-1076029618761005]^ The area under the ROC curve for PLR in that previous study was 0.78, and a PLR above 126 predicted no reflow with a sensitivity of 73% and specificity of 71%. A possible explanation for the different pattern of results between Kurtul et al and our study may be the relatively low platelet count in our study (237.0 × 10^9^/L in normal reflow group and 254.0 × 10^9^/L in no-reflow group in Kurtul et al vs 206.0 × 10^9^/L in normal reflow group and 216.5 × 10^9^/L in no-reflow group in our study). Our study included more patients with symptom onset \>6 hours (35.5% in our study vs 8.5% in Kurtul et al) which may result in the consumption of platelets in the infarct region or thrombi formation and the reverse changes in MPV.^[@bibr27-1076029618761005]^ These inconsistent results indicate that the utility of hematological parameters, such as PLR and MPVLR, may vary with the timing of STEMI onset. For the first time in our study, we demonstrated the predicting value of MPVLR for the no-reflow phenomenon in patients with STEMI. Many studies have shown a negative correlation between platelet count and MPV.^[@bibr27-1076029618761005],[@bibr28-1076029618761005]^ So it is not surprising that PLR and MPVLR displayed same predictive value for no reflow in the present study.

Monocytes and lymphocytes are both key immune cells in the inflammatory response. Previous study revealed that the area under the ROC curve for the LMR for the no-reflow phenomenon was 0.835. The cutoff value of the LMR (2.292) was associated with 76.3% sensitivity and 72.5% specificity, respectively.^[@bibr29-1076029618761005]^ However, there was relatively lower predictive capacity of LMR in our study with AUC = 0.620, 46.0% sensitivity, and 77.7% specificity, respectively. The discordance between these 2 studies may be partially due to the different sample sizes and clinical characteristics.

Study Limitations {#section9-1076029618761005}
-----------------

This study investigated the comparative value of admission hematological parameters in predicting the no-reflow phenomenon for patients with STEMI treated with PPCI. However, this is a retrospective study, including a relatively small number of patients, and it was conducted at a single institution. These factors may have hindered our ability to identify differences among studied parameters, and the power of the analysis of our study might be restricted. We did not assess the effect of reference luminal diameter in the present study, which may be correlated with no reflow during PPCI and may influence the evaluation of the predictive value of the studied hematological parameters. Additional large-scale, prospective studies will be needed to further evaluate the comparative abilities of various hematological parameters to predict the no-reflow phenomenon.

Conclusion {#section10-1076029618761005}
==========

We found that MPVLR and other previously studied hematological parameters, including neutrophil count, NLR, PLR, and LMR, showed a moderate diagnostic performance regarding the prediction of no reflow. The diagnostic abilities of these hematological parameters performed similarly, and no parameter had persuasive superior diagnostic capacities to identify the no-reflow phenomenon in patients with STEMI receiving PPCI.
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